Efficacy of Mydriatic Drops in Premature Infants

Sponsor
Bulent Ecevit University (Other)
Overall Status
Completed
CT.gov ID
NCT03448640
Collaborator
(none)
60
23

Study Details

Study Description

Brief Summary

Because of the neonatologists reported that some infants had suffered from vomiting, bradycardia, hypotonia, and aspiration risk about 30-60 minutes after the fundus examination in the intensive care unit. The investigators observed the pupil dilation effects and side effects of tipple instillation of phenylephrine 2.5% plus tropicamide 0.5% ophthalmic drop combination which the investigators routinely used in ROP examination.

Condition or Disease Intervention/Treatment Phase
  • Drug: Drug used in the examination of premature infants.

Detailed Description

Purpose: To determine effect and vital change after topical application of phenylephrine 2.5% and tropicamide 0.5% three times for retinopathy of prematurity (ROP) examination in preterm infants.

Methods: Pupillary diameter, blood pressure, pulse rate, and oxygen saturation were monitored before, and after up to 24 hours 60 ROP screening examinations.

Study Design

Study Type:
Observational
Actual Enrollment :
60 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Efficiency and Safety of Phenylephrine and Tropicamide Used in Premature Retinopathy
Actual Study Start Date :
Jan 15, 2016
Actual Primary Completion Date :
Oct 15, 2017
Actual Study Completion Date :
Dec 15, 2017

Outcome Measures

Primary Outcome Measures

  1. The mean pupillary diameter [an average of 1 year]

    will be measured with a ruler after 60 minutes instillation of mydriatic

Eligibility Criteria

Criteria

Ages Eligible for Study:
32 Weeks to 34 Weeks
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Infants who were first ROP examinations

  • infants born before 32 weeks.

Exclusion Criteria:
  • Developmental ocular and/or systemic anomalies.

  • Drug use that can affect vital values

  • Unstable general condition

  • Food intolerance

  • Recurrent vomiting.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Bulent Ecevit University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Atilla Alpay, Asociate Pofessor Atilla Alpay, Bulent Ecevit University
ClinicalTrials.gov Identifier:
NCT03448640
Other Study ID Numbers:
  • BulentEU
First Posted:
Feb 28, 2018
Last Update Posted:
Feb 28, 2018
Last Verified:
Feb 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 28, 2018